|
- Mallinckrodt Pharmaceuticals | Global Specialty Pharmaceutical Company . . .
As a global specialty pharmaceutical company, Mallinckrodt has been making the complex simple for more than 150 years Visit the website to learn more
- Mallinckrodt - Wikipedia
Mallinckrodt Mallinckrodt Pharmaceuticals plc is an American-Irish domiciled manufacturer of specialty pharmaceuticals (namely, adrenocorticotropic hormone), generic drugs and imaging agents [2] In 2017, it generated 90% of its sales from the U S healthcare system
- Home | Mallinckrodt Endo
Mallinckrodt and Endo are merging to create a leading global therapeutics company with branded and generic products Stay tuned for updates
- Mallinckrodt plc Reports Financial Results for Second . . . - BioSpace
Mallinckrodt's performance demonstrates continued positive momentum and strong execution, including the highest quarter of growth for the Acthar ® Gel brand in more than a decade Endo also continued advancing key growth drivers, as evidenced by strong XIAFLEX ® performance and the advancement of the Sterile Injectables pipeline
- Our Products | Mallinckrodt Pharmaceuticals
Mallinckrodt has a diverse portfolio of branded products available across a broad range of indications and a broad line of speciality generics Visit our website to learn about our product offerings
- Drugmaker Mallinckrodt emerges from bankruptcy | Reuters
Mallinckrodt, which makes branded and generic drugs, first filed for bankruptcy in 2020 to address its high debt load, litigation over its allegedly deceptive marketing of highly addictive
- Mallinckrodt Pharmaceuticals - Listening for Needs. Delivering Solutions
About Us Solving complex challenges with a diverse product portfolio Mallinckrodt is a global specialty pharmaceutical business that develops, manufactures, markets and distributes specialty pharmaceutical products
- Mallinckrodt, Endo Complete Merger to Create Global, Scaled . . .
DUBLIN, Aug 1, 2025 PRNewswire -- Mallinckrodt plc and Endo, Inc today announced that they have completed their merger to create a global, scaled, diversified therapeutics leader "We are
|
|
|